Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

FLT3-ITD Signaling Continuously Degrades p53 By the Ubiquitin-Proteosome Pathway Explaining Chemo-Resistance

Xiaorong Gu, Zeinab Albadry M. Zahran, Ramesh Balusu, Jaroslaw Maciejewski, Babal K. Jha, Yogenthiran Saunthararajah

Blood (2024) 144 (Supplement 1): 2714.

https://doi.org/10.1182/blood-2024-205887

Published: 2024

Journal Articles

B- Cell Maturation Antigen (BCMA) Re-Emergence and Relapse Patterns Post-BCMA-Chimeric Antigen Receptor T Cell (CAR-T ) Therapy for Multiple Myeloma

William Wesson, Wei Cui, Muhammad Mushtaq, Rajat Bansal, Anurag K. Singh, Marc Hoffmann, Aung M Tun, Ramesh Balusu, Haitham Abdelhakim, Sunil H Abhyankar, Joseph P. McGuirk, Leyla O. Shune, Al-Ola Abdallah, Nausheen Ahmed

Blood (2022) 140 (Supplement 1): 12781–12783.

https://doi.org/10.1182/blood-2022-160437

Published: 2022

Journal Articles

Lessons Learned from COVID-19 Pandemic: Outcomes after Sars-Cov-2 Infection in Hematopoietic Cell Transplant and Cell Therapy Recipients

Muhammad Umair Mushtaq, Joe S Al-Ramahi, Kevin S Li, Moazzam Shahzad, Sibgha Gull Chaudhary, Ramesh Balusu, Nausheen Ahmed, Rajat Bansal, Haitham Abdelhakim, Leyla O. Shune, Anurag K. Singh, Sunil H Abhyankar, Joseph P. McGuirk

Blood (2022) 140 (Supplement 1): 10481–10483.

https://doi.org/10.1182/blood-2022-158716

Published: 2022

Journal Articles

Outcomes with "Off the Shelf" Allogeneic CD19 Chimeric Antigen Receptor T Cell Therapy for Hematological Malignancies: A Systematic Review and Meta-Analysis

Muhammad Umair Mushtaq, Moazzam Shahzad, Ali Hussain, Amna Y Shah, Raheel S Siddiqui, Muhammad Salman Faisal, Iqra Anwar, Sibgha Gull Chaudhary, Ghulam Rehman Mohyuddin, Ramesh Balusu, Aung M Tun, Rajat Bansal, Haitham Abdelhakim, Marc Hoffmann, Anurag K. Singh, Leyla Shune, Sunil Abhyankar, Joseph P. McGuirk, Nausheen Ahmed

Blood (2021) 138 (Supplement 1): 4831.

https://doi.org/10.1182/blood-2021-148999

Published: 2021

Journal Articles

Outcomes with Venetoclax in Relapsed Acute Myeloid Leukemia after Allogenic Hematopoietic Stem Cell Transplantation: A Systemic Review and Meta-Analysis

Pranali Santhoshini Pachika, Moazzam Shahzad, Razwana Khanam, Adeel Masood, Zahoor Ahmed, S Fatima Ali, Asmi Chattaraj, Muhammad Tahir, Faiz Anwer, Ramesh Balusu, Sibgha Gull Chaudhary, Sunil Abhyankar, Nausheen Ahmed, Joseph P. McGuirk, Muhammad Umair Mushtaq

Blood (2021) 138 (Supplement 1): 4410.

https://doi.org/10.1182/blood-2021-145492

Published: 2021

Journal Articles

Use of Endpoints in Phase III Randomized Controlled Trials for Hematopoietic Stem Cell Transplantation over the Last 15 Years: A Systematic Review

Muhammad Umair Mushtaq, Moazzam Shahzad, Ezza Tariq, Muhammad Arslan, Sara Shahid, Raza Ur Rahman, Faryal Murtaza, Iqra Anwar, Qamar Iqbal, Sibgha Gull Chaudhary, Ramesh Balusu, Nausheen Ahmed, Peiman Hematti, Sunil Abhyankar, Joseph P. McGuirk, Leyla Shune

Blood (2021) 138 (Supplement 1): 4910.

https://doi.org/10.1182/blood-2021-146218

Published: 2021

Journal Articles

Impact of Natural Killer Cells Reconstitution on Outcomes after Allogenic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis

Moazzam Shahzad, Amna Y Shah, Muhammad Usman Zafar, Ezza Tariq, Anam Hamid, Ayna Serwat, Iqra Anwar, Sibgha Gull Chaudhary, Ramesh Balusu, Rajat Bansal, Nausheen Ahmed, Leyla Shune, Joseph P. McGuirk, Muhammad Umair Mushtaq

Blood (2021) 138 (Supplement 1): 4880.

https://doi.org/10.1182/blood-2021-146090

Published: 2021

Journal Articles

Outcomes with Hematopoietic Stem Cell Transplantation in Secondary Hemophagocytic Lymphohistiocytosis: A Systematic Review and Meta-Analysis

Qamar Iqbal, Moazzam Shahzad, Ezza Tariq, Laila Hashim, Abdul Basit, Kashf Zaidi, Muhammad Salman Faisal, Iqra Anwar, Sibgha Gull Chaudhary, Ramesh Balusu, Nausheen Ahmed, Leyla Shune, Peiman Hematti, Joseph P. McGuirk, Muhammad Umair Mushtaq

Blood (2021) 138 (Supplement 1): 3963.

https://doi.org/10.1182/blood-2021-149722

Published: 2021

Journal Articles

Outcomes with Mismatched Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation Following Reduced Intensity Conditioning: A Systematic Review and Meta-Analysis

Moazzam Shahzad, Sibgha Gull Chaudhary, Ezza Tariq, Naira Fatima, Muhammad Arslan, Muhammad Usman Zafar, Amna Y Shah, Mamoon Ahmed, Iqra Anwar, Nausheen Ahmed, Leyla Shune, Ramesh Balusu, Peiman Hematti, Joseph P. McGuirk, Muhammad Umair Mushtaq

Blood (2021) 138 (Supplement 1): 2863.

https://doi.org/10.1182/blood-2021-146051

Published: 2021

Journal Articles

Outcomes with Interferon in Essential Thrombocythemia: A Systematic Review and Meta-Analysis

Moazzam Shahzad, Mamoon Ahmed, Sakina Abbas, Muhammad Arslan, Tooba Kashif, Iqra Anwar, Ali Hussain, Qamar Iqbal, Sibgha Gull Chaudhary, Ramesh Balusu, Nausheen Ahmed, Joseph P. McGuirk, Muhammad Umair Mushtaq, Abdulraheem Yacoub

Blood (2021) 138 (Supplement 1): 3147.

https://doi.org/10.1182/blood-2021-145675

Published: 2021

Journal Articles

Outcomes with Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Chronic Lymphocytic Leukemia: A Systematic Review and Meta-Analysis

Moazzam Shahzad, Raheel S Siddiqui, Sakina Abbas, Sibgha Gull Chaudhary, Mamoon Ahmed, Amna Y Shah, Muhammad Arslan, Iqra Anwar, Ramesh Balusu, Rajat Bansal, Nausheen Ahmed, Leyla Shune, Peiman Hematti, Joseph P. McGuirk, Muhammad Umair Mushtaq

Blood (2021) 138 (Supplement 1): 4683.

https://doi.org/10.1182/blood-2021-145505

Published: 2021

Journal Articles

Preclinical Evaluation of Gilteritinib on NPM1-ALK Driven Anaplastic Large Cell Lymphoma Cells

Sudhakiranmayi Kuravi, M.S., Janice Cheng, MD, Kishore Polireddy, PhD, Gabrielle Fangman, B.S., Roy A Jensen, MD, Tara L. Lin, MD, Siddhartha Ganguly, MD, Joseph P. McGuirk, DO, Ramesh Balusu, PhD

Blood (2019) 134 (Supplement_1): 2865.

https://doi.org/10.1182/blood-2019-130633

Published: 2019

Journal Articles

CDC37 As a Novel Target for the Treatment of NPM1-ALK Expressing Anaplastic Large Cell Lymphomas

Sudhakiranmayi Kuravi, M.S., Elizabeth Parrott, M.A., Siddhartha Ganguly, MD, Anusha Vallurupalli, MD, Yogenthiran Saunthararajah, MD, Brian S Blagg, PhD, Jensen Roy, MD, Joseph P. McGuirk, DO, Ramesh Balusu, PhD

Blood (2017) 130 (Supplement 1): 2758.

https://doi.org/10.1182/blood.V130.Suppl_1.2758.2758

Published: 2017

Journal Articles

The Mechanisms By Which Mutant-NPM1 Uncouples Differentiation from Proliferation Are Reversed By Several Drugs, Enabling Rational Multi-Component Non-Cytotoxic Differentiation Therapy

Xiaorong Gu, PhD, Quteba Ebrahem, MD, Reda Z. Mahfouz, MD PhD, Metis Hasipek, PhD, Francis Enane, PhD, Tomas Radivoyevitch, Nicolas Rapin, PhDMSc, Bartlomiej P. Przychodzen, MSc, Ramesh Balusu, PhD, Claudiu V Cotta, David Wald, MD PhD, Zhenbo Hu, MD PhD, Yosef Landesman, PhD, Maria Paola Martelli, MD PhD, Brunangelo Falini, MD, Hetty E. Carraway, MD MBA, Jaroslaw P. Maciejewski, PhD MD FACP, Babal K Jha, PhD, Yogenthiran Saunthararajah, MD

Blood (2017) 130 (Supplement 1): 878.

https://doi.org/10.1182/blood.V130.Suppl_1.878.878

Published: 2017

Journal Articles

The Mechanism By Which Mutant Nucleophosmin (NPM1) Creates Leukemic Self-Renewal Is Readily Reversed

Xiaorong Gu, PhD, Reda Z. Mahfouz, MD, PhD, Quteba Ebrahem, Francis Enane, Tomas Radivoyevitch, PhD, Michael J. Clemente, M.S., Bartlomiej P Przychodzen, MSc, Zhenbo Hu, MD PhD, Ramesh Balusu, PhD, Claudiu V. Cotta, MD, David N. Wald, MDPhD, Yosef Landesman, PhD, Maria Paola Martelli, MD PhD, Brunangelo Falini, Jaroslaw P Maciejewski, MD PhD FACP, Yogenthiran Saunthararajah, MD

Blood (2016) 128 (22): 444.

https://doi.org/10.1182/blood.V128.22.444.444

Published: 2016

Journal Articles

NPM1-TYK2 Fusion Is an Oncogene and a Novel HSP90-Client Protein

Sudhakiranmayi Kuravi, M.S., Preethi Kunchala, M.S., Siddhartha Ganguly, MD, Sunil Abhyankar, MD, Yogen Saunthararajah, MD, Kojo S. J. Elenitoba-Johnson, MD, Jensen Roy, MD, Joseph McGuirk, DO, Ramesh Balusu, PhD

Blood (2016) 128 (22): 4127.

https://doi.org/10.1182/blood.V128.22.4127.4127

Published: 2016

Journal Articles

Targeting Mutant Nucleophosmin 1 (NPM1) Induces Differentiation, Loss of Survival and Sensitizes AML Cells to All-Trans Retinoic Acid, Cytarbine and FLT3 Antagonists

Ramesh Balusu, PhD, Josiah Cox, Stacey Hembruff, MS, Warren Fiskus, BSc, PhD, Rekha Rao, PhD, Uma Mudunuru, MS, Ruben Reyes, MD, Siddhartha Ganguly, MD, Sunil Abhyankar, MD, Heather Male, MD, Allan Fleming, MD, Casey B Williams, Pharm.D., Joseph McGuirk, DO, Kapil N. Bhalla, MD

Blood (2011) 118 (21): 733.

https://doi.org/10.1182/blood.V118.21.733.733

Published: 2011

Journal Articles

Combined Targeting of Chromatin Modifying Enzymes LSD1, EZH2 and Histone Deacetylases (HDACs) Has Superior Efficacy Against Human Mantle Cell Lymphoma Cells

Warren Fiskus, PhD, Sunil Sharma, MD, Rekha Rao, PhD, Ramesh Balusu, PhD, Sreedhar Venkannagari, PhD, Stacey Hembruff, MS, Siddhartha Ganguly, MD, Eduardo M. Sotomayor, Jianguo Tao, MD, PhD, David J. Bearss, PhD, Kapil N. Bhalla, MD

Blood (2011) 118 (21): 2429.

https://doi.org/10.1182/blood.V118.21.2429.2429

Published: 2011

Journal Articles

Targeting levels or oligomerization of nucleophosmin 1 induces differentiation and loss of survival of human AML cells with mutant NPM1

Ramesh Balusu, Warren Fiskus, Rekha Rao, Daniel G. Chong, Srilatha Nalluri, Uma Mudunuru, Hongwei Ma, Lei Chen, Sreedhar Venkannagari, Kyungsoo Ha, Sunil Abhyankar, Casey Williams, Joseph McGuirk, Hanna Jean Khoury, Celalettin Ustun, Kapil N. Bhalla

Blood (2011) 118 (11): 3096–3106.

https://doi.org/10.1182/blood-2010-09-309674

Published: 2011

Includes: Supplemental data

Journal Articles

Pan-histone deacetylase inhibitor panobinostat depletes CXCR4 levels and signaling and exerts synergistic antimyeloid activity in combination with CXCR4 antagonists

Aditya Mandawat, Warren Fiskus, Kathleen M. Buckley, Kelly Robbins, Rekha Rao, Ramesh Balusu, Jean-Marc Navenot, Zi-Xuan Wang, Celalettin Ustun, Daniel G. Chong, Peter Atadja, Nobutaka Fujii, Stephen C. Peiper, Kapil Bhalla

Blood (2010) 116 (24): 5306–5315.

https://doi.org/10.1182/blood-2010-05-284414

Published: 2010

NARROW

FLT3-ITD Signaling Continuously Degrades p53 By the Ubiquitin-Proteosome Pathway Explaining Chemo-Resistance

B- Cell Maturation Antigen (BCMA) Re-Emergence and Relapse Patterns Post-BCMA-Chimeric Antigen Receptor T Cell (CAR-T ) Therapy for Multiple Myeloma

Lessons Learned from COVID-19 Pandemic: Outcomes after Sars-Cov-2 Infection in Hematopoietic Cell Transplant and Cell Therapy Recipients

Outcomes with "Off the Shelf" Allogeneic CD19 Chimeric Antigen Receptor T Cell Therapy for Hematological Malignancies: A Systematic Review and Meta-Analysis

Outcomes with Venetoclax in Relapsed Acute Myeloid Leukemia after Allogenic Hematopoietic Stem Cell Transplantation: A Systemic Review and Meta-Analysis

Use of Endpoints in Phase III Randomized Controlled Trials for Hematopoietic Stem Cell Transplantation over the Last 15 Years: A Systematic Review

Impact of Natural Killer Cells Reconstitution on Outcomes after Allogenic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis

Outcomes with Hematopoietic Stem Cell Transplantation in Secondary Hemophagocytic Lymphohistiocytosis: A Systematic Review and Meta-Analysis

Outcomes with Mismatched Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation Following Reduced Intensity Conditioning: A Systematic Review and Meta-Analysis

Outcomes with Interferon in Essential Thrombocythemia: A Systematic Review and Meta-Analysis

Outcomes with Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Chronic Lymphocytic Leukemia: A Systematic Review and Meta-Analysis

Preclinical Evaluation of Gilteritinib on NPM1-ALK Driven Anaplastic Large Cell Lymphoma Cells

CDC37 As a Novel Target for the Treatment of NPM1-ALK Expressing Anaplastic Large Cell Lymphomas

The Mechanisms By Which Mutant-NPM1 Uncouples Differentiation from Proliferation Are Reversed By Several Drugs, Enabling Rational Multi-Component Non-Cytotoxic Differentiation Therapy

The Mechanism By Which Mutant Nucleophosmin (NPM1) Creates Leukemic Self-Renewal Is Readily Reversed

NPM1-TYK2 Fusion Is an Oncogene and a Novel HSP90-Client Protein

Targeting Mutant Nucleophosmin 1 (NPM1) Induces Differentiation, Loss of Survival and Sensitizes AML Cells to All-Trans Retinoic Acid, Cytarbine and FLT3 Antagonists

Combined Targeting of Chromatin Modifying Enzymes LSD1, EZH2 and Histone Deacetylases (HDACs) Has Superior Efficacy Against Human Mantle Cell Lymphoma Cells

Targeting levels or oligomerization of nucleophosmin 1 induces differentiation and loss of survival of human AML cells with mutant NPM1

Pan-histone deacetylase inhibitor panobinostat depletes CXCR4 levels and signaling and exerts synergistic antimyeloid activity in combination with CXCR4 antagonists

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only